BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27384850)

  • 21. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
    Assmus B; Cremer S; Kirschbaum K; Culmann D; Kiefer K; Dorsheimer L; Rasper T; Abou-El-Ardat K; Herrmann E; Berkowitsch A; Hoffmann J; Seeger F; Mas-Peiro S; Rieger MA; Dimmeler S; Zeiher AM
    Eur Heart J; 2021 Jan; 42(3):257-265. PubMed ID: 33241418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tet2 restrains inflammatory gene expression in macrophages.
    Cull AH; Snetsinger B; Buckstein R; Wells RA; Rauh MJ
    Exp Hematol; 2017 Nov; 55():56-70.e13. PubMed ID: 28826859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease.
    Sano S; Oshima K; Wang Y; Katanasaka Y; Sano M; Walsh K
    Circ Res; 2018 Jul; 123(3):335-341. PubMed ID: 29728415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variations.
    Hernández-Sánchez M; Rodríguez AE; Kohlmann A; Benito R; García JL; Risueño A; Fermiñán E; De Las Rivas J; González M; Hernández-Rivas JM
    Biomed Res Int; 2014; 2014():814294. PubMed ID: 24693539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.
    Guan Y; Tiwari AD; Phillips JG; Hasipek M; Grabowski DR; Pagliuca S; Gopal P; Kerr CM; Adema V; Radivoyevitch T; Parker Y; Lindner DJ; Meggendorfer M; Abazeed M; Sekeres MA; Mian OY; Haferlach T; Maciejewski JP; Jha BK
    Blood Cancer Discov; 2021 Mar; 2(2):146-161. PubMed ID: 33681816
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of TET2 mutations in myeloproliferative neoplasms.
    Pronier E; Delhommeau F
    Curr Hematol Malig Rep; 2012 Mar; 7(1):57-64. PubMed ID: 22200996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
    Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
    Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Divergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness.
    Ostrander EL; Kramer AC; Mallaney C; Celik H; Koh WK; Fairchild J; Haussler E; Zhang CRC; Challen GA
    Stem Cell Reports; 2020 Apr; 14(4):551-560. PubMed ID: 32220332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
    Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
    J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human blood cell levels of 5-hydroxymethylcytosine (5hmC) decline with age, partly related to acquired mutations in TET2.
    Buscarlet M; Tessier A; Provost S; Mollica L; Busque L
    Exp Hematol; 2016 Nov; 44(11):1072-1084. PubMed ID: 27475703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutation analysis of therapy-related myeloid neoplasms.
    Nishiyama T; Ishikawa Y; Kawashima N; Akashi A; Adachi Y; Hattori H; Ushijima Y; Kiyoi H
    Cancer Genet; 2018 Apr; 222-223():38-45. PubMed ID: 29666007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperglycemia cooperates with Tet2 heterozygosity to induce leukemia driven by proinflammatory cytokine-induced lncRNA Morrbid.
    Cai Z; Lu X; Zhang C; Nelanuthala S; Aguilera F; Hadley A; Ramdas B; Fang F; Nephew K; Kotzin JJ; Williams A; Henao-Mejia J; Haneline L; Kapur R
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33090974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell of origin epigenetic priming determines susceptibility to Tet2 mutation.
    Schiroli G; Kartha V; Duarte FM; Kristiansen TA; Mayerhofer C; Shrestha R; Earl A; Hu Y; Tay T; Rhee C; Buenrostro JD; Scadden DT
    Nat Commun; 2024 May; 15(1):4325. PubMed ID: 38773071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
    Wang R; Gao X; Yu L
    BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TET2 Promoter DNA Methylation and Expression in Childhood Acute Lymphoblastic Leukemia.
    Bahari G; Hashemi M; Naderi M; Taheri M
    Asian Pac J Cancer Prev; 2016; 17(8):3959-62. PubMed ID: 27644645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.
    Dominguez PM; Ghamlouch H; Rosikiewicz W; Kumar P; Béguelin W; Fontán L; Rivas MA; Pawlikowska P; Armand M; Mouly E; Torres-Martin M; Doane AS; Calvo Fernandez MT; Durant M; Della-Valle V; Teater M; Cimmino L; Droin N; Tadros S; Motanagh S; Shih AH; Rubin MA; Tam W; Aifantis I; Levine RL; Elemento O; Inghirami G; Green MR; Figueroa ME; Bernard OA; Aoufouchi S; Li S; Shaknovich R; Melnick AM
    Cancer Discov; 2018 Dec; 8(12):1632-1653. PubMed ID: 30274972
    [No Abstract]   [Full Text] [Related]  

  • 38. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
    Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
    Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia.
    Wang J; He N; Wang R; Tian T; Han F; Zhong C; Zhang C; Hua M; Ji C; Ma D
    Sci Rep; 2020 Feb; 10(1):2706. PubMed ID: 32066746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic treatment ameliorates Ten-eleven translocation 2 (TET2) loss-of-function associated hematological malignancies.
    Zeng H; He H; Guo L; Li J; Lee M; Han W; Guzman AG; Zang S; Zhou Y; Zhang X; Goodell MA; King KY; Sun D; Huang Y
    Cancer Lett; 2019 Dec; 467():1-8. PubMed ID: 31563562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.